SSY Group Wins NMPA Approval for Acetylcysteine and Compound Sodium Acetate Ringer's Injections

Reuters12-11
SSY Group Wins NMPA Approval for Acetylcysteine and Compound Sodium Acetate Ringer's Injections

SSY Group Ltd. has announced that it has received approval from the National Medical Products Administration of China (NMPA) for the production and registration of two pharmaceutical products. The approvals cover Acetylcysteine Injection (25ml: 5g), used for the detoxification of acute acetaminophen poisoning, and Compound Sodium Acetate Ringer's Injection (500ml), used for supplementing extracellular fluid and correcting metabolic acidosis. Both products are classified as type 3 chemical drugs and have passed the required consistency evaluation. No other organizations were mentioned as recipients of these approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251211-11952106), on December 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment